RMTG's Net Loss Widens 30% on Soaring Interest Costs

TL;DR

**RMTG is drowning in debt and interest payments, making its revenue growth irrelevant; steer clear.**

AI Summary

Regenerative Medical Technology Group Inc. (RMTG) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $(6,419,566) compared to $(4,924,785) for the same period in 2024. This 30.35% increase in net loss was primarily driven by a substantial rise in interest expense, which surged to $(5,440,183) in 2025 from $(4,621,920) in 2024, and a loss on extinguishment of debt of $(416,155) in 2025. Despite the increased losses, revenue grew by 35.86% to $3,528,393 for the nine months ended September 30, 2025, up from $2,596,671 in 2024. However, cost of revenue also increased significantly to $1,497,110 from $753,735, impacting gross profit margins. The company's total liabilities increased to $34,574,268 as of September 30, 2025, from $31,178,101 at December 31, 2024, largely due to a rise in long-term notes payable to $16,943,831 from $1,999,999. Cash and cash equivalents saw a modest increase to $1,185,695 from $1,165,820, but operating activities consumed $(744,715) in cash during the nine-month period.

Why It Matters

This filing reveals RMTG's struggle with profitability despite revenue growth, primarily due to a massive interest expense burden and debt extinguishment losses. For investors, the escalating accumulated deficit of $(73,972,668) and significant long-term debt raise serious concerns about the company's financial viability and ability to sustain operations without further dilutive financing or debt restructuring. Employees and customers might face uncertainty regarding the company's long-term stability in the competitive regenerative medicine market. The substantial debt and ongoing losses could limit RMTG's ability to invest in R&D or expand its stem cell therapy offerings, potentially hindering its competitive position against larger, better-capitalized players.

Risk Assessment

Risk Level: high — The company exhibits a high risk level due to an accumulated deficit of $(73,972,668) as of September 30, 2025, and a net loss of $(6,419,566) for the nine months ended September 30, 2025. Furthermore, total liabilities significantly exceed total assets, with $34,574,268 in liabilities against $4,519,827 in assets, indicating severe financial distress and a going concern risk.

Analyst Insight

Investors should exercise extreme caution and consider divesting any holdings in RMTG. The company's substantial debt, increasing losses, and negative stockholders' deficit suggest a high probability of further dilution or potential bankruptcy. Focus on companies with stronger balance sheets and clear paths to profitability in the regenerative medicine sector.

Financial Highlights

debt To Equity

N/A

revenue

$3.53M

operating Margin

N/A

total Assets

$4.52M

total Debt

$34.57M

net Income

-$6.42M

eps

N/A

gross Margin

57.57%

cash Position

$1.19M

revenue Growth

+35.86%

Key Numbers

• $6.42M — Net Loss (Increased from $4.92M in 2024 for the nine months ended September 30, 2025, a 30.35% increase.)
• $5.44M — Interest Expense (Increased from $4.62M in 2024 for the nine months ended September 30, 2025, a 17.75% increase.)
• $3.53M — Revenue (Increased from $2.60M in 2024 for the nine months ended September 30, 2025, a 35.86% increase.)
• $73.97M — Accumulated Deficit (Increased from $67.55M at December 31, 2024, indicating ongoing losses.)
• $34.57M — Total Liabilities (Increased from $31.18M at December 31, 2024, highlighting significant debt burden.)
• $16.94M — Long-term Notes Payable (Increased substantially from $2.00M at December 31, 2024, indicating a shift in debt structure.)
• $(744,715) — Cash Used in Operating Activities (A significant outflow compared to $471,306 cash provided in 2024, indicating operational cash burn.)
• $1.19M — Cash and Cash Equivalents (Slight increase from $1.17M at December 31, 2024, despite operational cash burn, likely due to new debt.)
• $416,155 — Loss on Extinguishment of Debt (A new expense in 2025, contributing to the increased net loss.)
• 12,538,968 — Common Shares Outstanding (Remained stable for the nine months ended September 30, 2025, compared to 2024.)

Key Players & Entities

• Regenerative Medical Technology Group Inc. (company) — registrant
• Global Stem Cells Group Inc. (company) — wholly-owned subsidiary
• Cellular Hope Institute (company) — wholly-owned subsidiary of Global Stem Cells Group Inc.
• Melvin Pereira (person) — prior officer and director, CEO of Pure Hospitality Solutions
• Meso Numismatics Corp. (company) — acquired entity, later divested
• Lans Holdings Inc. (company) — recipient of cash payment for preferred stock termination
• $6,419,566 (dollar_amount) — net loss for nine months ended September 30, 2025
• $5,440,183 (dollar_amount) — interest expense for nine months ended September 30, 2025
• $3,528,393 (dollar_amount) — revenue for nine months ended September 30, 2025
• $34,574,268 (dollar_amount) — total liabilities as of September 30, 2025

FAQ

Risk Factors

• Increasing Debt Burden and Interest Expense [high — financial]: Total liabilities have increased to $34.57 million as of September 30, 2025, from $31.18 million at December 31, 2024. This is largely driven by a significant rise in long-term notes payable to $16.94 million from $1.99 million. Concurrently, interest expense for the nine months ended September 30, 2025, surged to $5.44 million, up from $4.62 million in the prior year, contributing to a 30.35% increase in net loss.
• Growing Net Loss Despite Revenue Increase [high — financial]: The company reported a net loss of $6.42 million for the nine months ended September 30, 2025, a 30.35% increase from $4.92 million in the same period of 2024. This occurred despite a 35.86% increase in revenue to $3.53 million. The widening loss is exacerbated by a substantial increase in the cost of revenue, which more than doubled to $1.50 million from $0.75 million, significantly impacting gross profit margins.
• Negative Operating Cash Flow [medium — operational]: For the nine months ended September 30, 2025, the company consumed $744,715 in cash from operating activities. This is a reversal from the $471,306 cash provided by operating activities in the comparable period of 2024, indicating an increasing operational cash burn that requires external financing.
• Loss on Extinguishment of Debt [medium — financial]: The company incurred a new expense of $416,155 in the nine months ended September 30, 2025, representing a loss on extinguishment of debt. This non-recurring charge further contributed to the overall increase in net loss for the period.
• Accumulated Deficit Growth [high — financial]: The accumulated deficit has grown to $73.97 million as of September 30, 2025, from $67.55 million at December 31, 2024. This trend underscores the company's history of net losses and its ongoing challenge in achieving profitability.
• Increased Cost of Revenue [medium — operational]: The cost of revenue more than doubled to $1,497,110 for the nine months ended September 30, 2025, from $753,735 in the prior year. This significant increase outpaced revenue growth, leading to compressed gross profit margins and contributing to the overall net loss.

Industry Context

The regenerative medical technology sector is characterized by high research and development costs, long product development cycles, and significant regulatory hurdles. Companies in this space often rely on substantial funding to advance novel therapies and technologies. The competitive landscape includes established pharmaceutical companies and numerous emerging biotech firms, all vying for market share and investor capital.

Regulatory Implications

Companies in the regenerative medicine space face stringent regulatory oversight from bodies like the FDA. Delays in clinical trials, failure to meet efficacy or safety standards, or changes in regulatory pathways can significantly impact product approval timelines and market access, posing a substantial risk to financial performance.

What Investors Should Do

1. Monitor the company's ability to manage its increasing debt load and interest expenses, particularly the substantial increase in long-term notes payable.
2. Analyze the sustainability of revenue growth in light of the rapidly increasing cost of revenue and widening net loss.
3. Evaluate the company's strategy for addressing its negative operating cash flow and its reliance on external financing.
4. Assess the impact of the loss on extinguishment of debt and its implications for future debt management strategies.
5. Consider the long-term viability of the business model given the growing accumulated deficit and the capital-intensive nature of regenerative medicine.

Glossary

Accumulated deficit

The cumulative net losses of a company that have not been offset by net income. It represents the total losses incurred since the company's inception. (Indicates the company's historical unprofitability, with the deficit increasing to $73.97 million as of September 30, 2025.)

Loss on extinguishment of debt

A loss recognized when a company repays or retires debt before its scheduled maturity date, often involving paying more than the carrying amount of the debt. (A new expense of $416,155 in 2025 that contributed to the increased net loss.)

Cost of revenue

The direct costs attributable to the production or purchase of the goods or services sold by a company. (Increased significantly to $1.50 million from $0.75 million, impacting gross profit margins.)

Right of use asset, net

An asset representing a lessee's right to use an underlying asset for the lease term, recognized under ASC 842 lease accounting standards. (Increased to $538,741 from $275,256, reflecting new lease arrangements.)

Accrued interest

Interest expense that has been incurred but not yet paid. (Significantly increased to $15.37 million from $10.50 million, reflecting higher debt levels and interest costs.)

Year-Over-Year Comparison

For the nine months ended September 30, 2025, Regenerative Medical Technology Group Inc. saw revenue grow by 35.86% to $3.53 million compared to the prior year. However, this growth was overshadowed by a 30.35% increase in net loss to $6.42 million, driven by a significant rise in interest expense and cost of revenue. Total liabilities also increased substantially, primarily due to a large jump in long-term notes payable, while operating activities consumed cash, contrasting with the prior year's positive cash flow from operations.

Filing Documents

• ea0266301-10q_regener.htm (10-Q) — 855KB
• ea026630101ex31-1_regener.htm (EX-31.1) — 10KB
• ea026630101ex31-2_regener.htm (EX-31.2) — 10KB
• ea026630101ex32-1_regener.htm (EX-32.1) — 4KB
• 0001213900-25-112710.txt ( ) — 5643KB
• mssv-20250930.xsd (EX-101.SCH) — 50KB
• mssv-20250930_cal.xml (EX-101.CAL) — 35KB
• mssv-20250930_def.xml (EX-101.DEF) — 266KB
• mssv-20250930_lab.xml (EX-101.LAB) — 448KB
• mssv-20250930_pre.xml (EX-101.PRE) — 281KB
• ea0266301-10q_regener_htm.xml (XML) — 589KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION Item 1. Condensed Consolidated Balance Sheets as of September 30, 2025 (unaudited) and December 31, 2024 1 Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2025, and 2024 (unaudited) 2 Condensed Consolidated Statements of Stockholders' Deficit for the Three and Nine Months Ended September 30, 2025, and 2024 (unaudited) 3 Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2025, and 2024 (unaudited) 5 Notes to Condensed Consolidated Financial Statements 6 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 26 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 44 Item 4.

Controls and Procedures

Controls and Procedures 44

OTHER INFORMATION

PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 45 Item 1A.

Risk Factors

Risk Factors 45 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 45 Item 3. Defaults Upon Senior Securities 45 Item 4. Mine Safety Disclosures 46 Item 5. Other Information 46 Item 6. Exhibits 46 i

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION Item 1.

Financial Statements

Financial Statements Regenerative Medical Technology Group Inc. CONDENSED CONSOLIDATED BALANCE SHEETS September 30, December 31, 2025 2024 (Unaudited) * ASSETS Current assets Cash and cash equivalents $ 1,185,695 $ 1,165,820 Accounts receivable 114,006 22,605 Inventory 155,886 10,115 Prepaid expenses 54,864 49,685 Total current assets 1,510,451 1,248,225 Property and equipment, net 677,544 451,703 Other assets 27,264 7,264 Intangible assets, net 85,849 159,004 Right of use asset, net 538,741 275,256 Goodwill 1,679,978 1,679,978 Total assets $ 4,519,827 $ 3,821,429 LIABILITIES AND STOCKHOLDERS' DEFICIT Current liabilities Accounts payable and accrued liabilities $ 337,595 $ 563,703 Accrued interest 15,368,806 10,504,901 Customer advances 172,146 55,684 Derivative liability 7,029 4,689 Lease liability, current portion 186,516 63,540 Convertible notes payable, net 43,138 43,138 Notes payable-related parties 7,800 7,800 Notes payable, net 1,150,135 17,722,932 Total current liabilities 17,273,165 28,966,386 Long term liabilities Lease liability, net of current portion 357,272 211,716 Notes payable, net of current portion 16,943,831 1,999,999 Total liabilities 34,574,268 31,178,101 Commitments and contingencies (see Note 7) - - Stockholders' deficit Preferred stock, $ 0.001 par value: 1,050,000 shares authorized as Series AA: 1,050,000 issued and outstanding as of September 30, 2025, and December 31, 2024, respectively 1,050 1,050 Preferred stock, $ 0.001 par value; 1,000 shares authorized as Series CC: 1 and 0 issued and outstanding as of September 30, 2025, and December 31, 2024, respectively 1 - Preferred stock, $ 0.001 par value; 10,000 shares authorized as Series DD: 9,870 issued and outstanding as of September 30, 2025, and December 31, 2024, respectively 10 10 Common stock, $ 0.001 par value: 100,000,000 shares authorized: 12,538,968

View Full Filing

View this 10-Q filing on SEC EDGAR